As the cell death of tumor-infiltrating lymphocytes has been shown to exacerbate T cell exhaustion in several mouse models of cancer (59, 60), targeting Fgl2 may provide additional immunotherapeutic efficacy akin to therapeutic antibodies targeting myeloid-associated receptors such as LAIR-1/2 (ClinicalTrials.gov NCT04408599) (61, 62) and Siglec-15 (ClinicalTrials.gov NCT03665285) (63, 64) currently in clinical trials, or the more established PD-L1/L2 blockade (65, 66). This evidence concerns the gene FGL2 and neoplasm.